Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases

Experimental and Clinical Cardiology

Volumn 9, Issue 1, 2004, Pages 31-34

  Horvath, Beata ^a   Hegedus, Dalma ^a   Szapary, Laszlo ^a   Marton, Zsolt ^a   Alexy, Tamas ^a   Koltai, Katalin ^a   Czopf, Laszlo ^a   Wittmann, Istavan ^a   Juricskay, Istvan ^a   Toth, Kalman ^a   Kesmarky, Gabor ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Endothelial dysfunction; Marker; Vascular disorders; von Willebrand factor

Indexed keywords

GLYCOPROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CELL DAMAGE; CEREBROVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL VASCULAR DISEASE; PROTEIN ANALYSIS; STROKE;

EID: 2942676622     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Harker LA, Ross R, Glomset JA. The role of endothetiat cell injury and platelet response in atherogenesis. Thromb Haemostas 1978;39:312-21.
2. Boneu B, Abbai M, Plante J, Bierme R. Factor VIII complex and endothelial damage. Lancet 1975;305:1430.
3. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424.
4. Ewenstein BE. Vascular biology of von Willebrand factor. In: Vascular Endothelium. Born GV, Schwartz CJ, eds. Stuttgart: Schattauer GmbH, 1997:107-22.
5. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thrombosis Res 1989;53:387-94.
6. Pober JS. Cytokine-mediated activation of vascular endothelium. Am J Pathol 1988;133:426-33.
7. Blann AD, McCollum CN. von Willebrand factor, endothetial cell damage and atherosclerosis. Eur J Vasc Surg 1994;8:10-5.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
9. Fischer BE, Thomas KB, Dorner F. von Willebrand factor: measuring its antigen or function? Correlation between the level of antigen, activity, and multimer size using various detection systems. Thromb Res 1998;91:39-40.
10. Electronic statistic textbook. Electronic Statistics Textbook. Tulsa: StatSoft, 2004. . (Version current at February 23, 2004).
11. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 1992;326:242-50.
12. Minick CR, Alonso DR, Rankin L. Role of immunologic arterial injury in atherogenesis. Thromb Haemostas 1978;39:304-11.
13. Vita JA, Treasure CB, Yeung AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992;85:1390-7.
14. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary flow modulation in humans: Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993;92:652-62.
15. Kannel WB. Lipids, diabetes and coronary heart disease. Insights from the Framingham study. Am Heart J 1985;110:1100-7.
16. Lip GY, Blann AD. von Willebrand factor and its relevance to cardiovascular disorders. Br Heart J 1995;74:580-3.
17. Kario K, Matsuo T, Hoshide S, et al. Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients. Blood Coagul Fibrinolysis 1999;10:269-76.
18. Davies MJ. The role of plaque pathology in coronary thrombosis. Clin Cardiol 1997;20:1-7.
19. Isaka N, Tanigawa T, Nishikawa M, Nakano T. [High shear induced platelet aggregation (h-SIPA) and effects of antiplatelet therapy.] Nippon Rinsho 1998;56:2624-9. Japanese.
20. Soskin P, Wiesel ML, Mossard JM, et al. von Willebrand factor in coronary disease. Arch Mal Coeur Vaiss 1994;87:85-93.
21. Uchiyama S, Yamazaky M, Maruyama S, et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994;25:1547-51.
22. Liu L, Lin Z, Shen S. Changes of von Willebrand factor and antithrombin III levels in acute stroke: Differences between thrombotic and hemorrhagic stroke. Thromb Res 1993;72:353-8.
23. Lip GY, Blann AD, Faroqi IS, Zarifis J, Sagar G, Beevers DG. Abnormal hemorheology, endothelial dysfunction and thrombogenesis in relation to hypertension in acute (ictus <12 h) stroke patients: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis 2001;12:307-15.
24. Whincup PH, Danesh J, Walker M, et al. Von Willebrand factor and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2002;23:1764-70.